PCR assays are based on the detection of the toxin B gene while ELISA testing uses cell cytotoxicity.
To compare the two diagnostic techniques, researchers identified 136 pediatric patient stool samples positive for C. diff by PCR between October 2010 and July 2014, and then conducted ELISA tests on those stool samples
The results of the study showed 60 percent of the pediatric patients with C. diff diagnosed by PCR had no toxin detectable by ELISA. Additionally, ELISA-negative patients were less likely to have received an antibiotic recently compared with ELISA-positive patients.
“These results highlight the need to standardize laboratory criteria for the diagnosis of C. diff infections in children,” the authors concluded.
More articles on C. diff:
The clinical, financial & emotional benefits of molecular C. difficile testing
Probiotics could be the answer to preventing C. difficile in hospitals
Scientists make breakthrough in C. diff vaccine development
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.